PHVS:NASDAQPharvaris N.V. analysis

Pharvaris (PHVS) is trading at $28.94, barely above its 20‑day SMA of $29.80 and well below the 200‑day SMA of $25.53, indicating a bullish bias despite a modestly neutral RSI of 47.4. The MACD histogram is negative (-0.19) with a bearish signal, yet the overall trend direction is marked as bullish and the Fear & Greed Index sits at an Extreme Greed 89.05, suggesting strong market optimism. Volume is decreasing, volatility is high at 57% over 30 days, and beta is slightly above market at 1.06, pointing to a stock that can swing sharply on news. The upside/downside projection of ~60% upside versus ~20% downside, combined with a strong‑buy consensus from 13 analysts, underscores significant upside potential if upcoming Phase 3 data for deucrictibant XR materializes as expected.
Fundamentally, the company is cash‑rich ($247 M) with minimal debt ($0.74 M) but is burning cash (operating cash flow -$147 M) and posting negative earnings (trailing EPS -$3.16, forward EPS -$2.75) resulting in a negative PE and ROE. The price‑to‑book ratio of 5.93 is elevated for a biotech without revenue, highlighting valuation risk, while the lack of dividend makes income sustainability irrelevant.